Citi analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $389.00 (from $382.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'March 19, 2024 2:50 PM Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)March 18, 2024 4:04 PM Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'March 15, 2024 6:11 AM Madrigal Pharma (MDGL) option IV into FDA approves Madrigal Pharmaceuticals' RezdiffraMarch 15, 2024 3:48 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $397 at JMP Securities, ' We had strong conviction'March 15, 2024 3:11 AM B.Riley Upgrades Madrigal Pharmaceuticals (MDGL) to NeutralMarch 15, 2024 3:10 AM After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gainMarch 14, 2024 4:48 PM Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisMarch 14, 2024 4:16 PM Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosiMarch 14, 2024 4:15 PM Madrigal Pharma (MDGL) option implied volatility into FDA approvalMarch 14, 2024 3:51 PM Madrigal Pharma (MDGL): FDA Approves rezdiffraMarch 14, 2024 3:45 PM Madrigal Gets FDA Approval For NDA For RezdiffraMarch 14, 2024 3:45 PM Madrigal Pharma (MDGL) Halted, News PendingMarch 14, 2024 3:30 PM